The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 17: 2721 - 2728

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.17.016

Clinical Research

A Randomized controlled study on the efficacy of HAIC sequential DEB⁃TACE in the treatment of colorectal cancer liver metastasis

  • Mengying ZHANG ,
  • Yaokai MA ,
  • Yifan DU ,
  • Wei ZHANG ,
  • Bo ZHOU ,
  • Xiyi YANG
Expand
  • Department of Interventional Radiology，Shanghai Xuhui District Central Hospital，Shanghai 200030，Shanghai，ChinaCorrespongding author： YANG Xiyi E?mail： docyangxiyi@hotmail. com

Received date: 2025-04-26

  Online published: 2025-09-05

Fold

Abstract

Objective To analyze the efficacy of hepatic arterial infusion chemotherapy （HAIC） sequential drug-eluting beads transcatheter arterial chemoembolization （DEB-TACE） in the treatment of liver metastases from colorectal cancer. Methods 86 patients with colorectal cancer liver metastasis admitted to multiple centers from September 2022 to September 2023 were selected and divided into a control group （43 cases） and an experimental group （43 cases） according to the random number table method. The control group was treated with HAIC， and the experimental group was treated with HAIC sequential DEB-TACE. The clinical data and the changes of tumor markers and liver function indexes before and after treatment were compared between the two groups， and the short-term and long-term efficacy was evaluated， and the adverse reactions were recorded. Results After treatment， the levels of carcinoembryonic antigen， carbohydrate antigen 125， carbohydrate antigen 199， carbohydrate antigen 242， aspartate aminotransferase， alanine aminotransferase， alkaline phosphatase and γ-glutamyl transpeptidase in the two groups decreased （P < 0.05）， and those in the experimental group were lower than the control group （P < 0.05）. The proportion of repeated treatment in the experimental group was lower than that in the control group （P < 0.05）. The objective remission rate and disease control rate in the experimental group were 60.00% and 82.50% respectively， which were higher than 30.95% and 61.90% in the control group （P < 0.05）. There was no significant difference in the incidence of adverse reactions between the control group and the experimental group （P > 0.05）. The results of Kaplan-Meier survival curve showed that the overall survival rate and progression-free survival rate of the experimental group were higher than those of the control group （P < 0.05）. Conclusions HAIC sequential DEB-TACE can effectively remove tumor cells and improve liver function in patients with colorectal cancer liver metastasis， and it has good clinical efficacy and can prolong the survival time of patients.

Key words： colorectal cancer; liver metastasis; hepatic artery infusion chemotherapy; drug-eluting beads transcatheter arterial chemoembolization; randomized controlled trial

Cite this article

Mengying ZHANG , Yaokai MA , Yifan DU , Wei ZHANG , Bo ZHOU , Xiyi YANG . A Randomized controlled study on the efficacy of HAIC sequential DEB⁃TACE in the treatment of colorectal cancer liver metastasis[J]. The Journal of Practical Medicine, 2025 , 41(17) : 2721 -2728 . DOI: 10.3969/j.issn.1006-5725.2025.17.016

References

[1] SOLEIMANI A， SAEEDI N， AL-ASADY A M， et al. Colorectal cancer stem cell biomarkers： Biological traits and prognostic insights ［J］. Curr Pharm Des， 2024， 30（18）：1386-1397. doi:10.2174/0113816128291321240329050945
[2] NI Y， WANG W， LIU Y， et al. Causal associations between liver traits and Colorectal cancer： A Mendelian randomization study ［J］. BMC Med Genomics， 2023， 16（1）：316. doi:10.1186/s12920-023-01755-w
[3] TABBAL M， ALKHALIFA A M， ALQATTAN A S， et al. Salvage liver transplantation after resection of colorectal cancer liver metastasis with favorable outcomes： A case report and review of the literature ［J］. BMC Gastroenterol， 2021， 21（1）：191. doi:10.1186/s12876-021-01778-6
[4] SREE GANESH B， KAZI M， GOEL M， et al. Feasibility of hepatic artery infusion chemotherapy for colorectal liver metastasis in an indian setting ［J］. Indian J Surg Oncol， 2024， 15（）：275-280. doi:10.1007/s13193-023-01871-0
[5] 彭涛， 杨沔， 金梁斌， 等. 肝动脉灌注化疗联合瑞戈非尼治疗结直肠癌肝转移患者的临床研究［J］. 中国临床药理学杂志， 2024， 40（2）：185-189.
[6] CHEN Y C， HUANG C W， LI C C， et al. Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis ［J］. World J Surg Oncol， 2023， 21（1）：378. doi:10.1186/s12957-023-03253-w
[7] VOGL T J， LAHRSOW M. The role of conventional TACE （cTACE） and DEBIRI-TACE in colorectal cancer liver Metastases ［J］. Cancers （Basel）， 2022， 14（6）：1503. doi:10.3390/cancers14061503
[8] 中国医师协会外科医师分会， 中华医学会外科学分会胃肠外科学组， 中华医学会外科学分会结直肠外科学组， 等. 中国结直肠癌肝转移诊断和综合治疗指南（2020版）［J］. 中华消化外科杂志， 2020， 19（12）：1229-1242.
[9] GRAHAM M A， LOCKWOOD G F， GREENSLADE D， et al. Clinical pharmacokinetics of oxaliplatin： A critical review ［J］. Clin Cancer Res， 2000， 6（4）：1205-1218.
[10] 杨学宁， 吴一龙. 实体瘤治疗疗效评价标准-RECIST［J］. 循证医学， 2004， 4（2）：85-90，111.
[11] 刘梅， 李书苹， 穆宁， 等. 肝动脉持续灌注化疗治疗难治性结直肠癌肝转移12例临床观察［J］. 山东医药， 2023， 63（24）：64-66.
[12] 张希昊， 章馨允， 曹曼卿， 等. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较［J］. 外科理论与实践， 2022， 27（2）：152-157.
[13] 刘保旺， 窦剑， 王洋， 等. 肝癌肝移植术前降期中载药微球经动脉化疗栓塞应用效果观察［J］. 河北医学， 2023， 29（7）：1183-1188.
[14] 刘松， 于广计， 王庆东. DEBIRI-TACE联合瑞戈非尼三线以上治疗结直肠癌肝转移的疗效及影响因素分析［J］. 国际肿瘤学杂志， 2022， 49（7）：400-407.
[15] YUAN N， LI X， WANG M， et al. Gut microbiota alteration influences colorectal cancer metastasis to the liver by remodeling the liver immune microenvironment ［J］. Gut Liver， 2022， 16（4）：575-588. doi:10.5009/gnl210177
[16] WEN D， YANG Y S， GAO D Z， et al. Oridonin enhances the anti-metastasis effect of oxaliplatinliplatin on colorectal cancer liver metastasis ［J］. Bull Exp Biol Med， 2021， 172（1）：26-32. doi:10.1007/s10517-021-05324-y
[17] WANG F， HE M M， YAO Y C， et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer： A phase Ⅰb/Ⅱ clinical trial and gut microbiome analysis ［J］. Cell Rep Med， 2021， 2（9）：100383. doi:10.1016/j.xcrm.2021.100383
[18] 李国文， 黄满平， 黄斌， 等. 肝动脉灌注化疗（HAIC）在不可切除结直肠癌肝转移多线治疗耐药后的疗效分析［J］. 肿瘤药学， 2024， 14（1）：65-71.
[19] 李芳， 晏睿阳， 李凯杨， 等. 白藜芦醇联合伊立替康治疗结直肠癌的分子作用机制研究［J］. 中国中药杂志， 2023， 48（8）：2212-2221.
[20] LI H， ZHANG X， ZHAO W， et al. Efficacy of CalliSpheres? microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis ［J］. BMC Cancer， 2023， 23（1）：970. doi:10.1186/s12885-023-11350-y
[21] ZHANG H， WU C， CHEN M， et al. Drug-eluting bead transarterial chemoembolization （DEB-TACE） versus conventional transarterial chemoembolization （cTACE） in colorectal liver metastasis： Efficacy， safety， and prognostic factors ［J］. J Cancer Res Ther， 2023， 19（6）：1525-1532. doi:10.4103/jcrt.jcrt_2143_22
[22] NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines?） for Colon Cancer. Version 1.2024. National Comprehensive Cancer Network. Available at： https：//www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
[23] BROWN K T， DO R K， GONEN M， et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone ［J］. J Clin Oncol， 2016， 34（17）：2046-2053. doi:10.1200/jco.2015.64.0821
Options
Outlines

/

〈 〉